Find the products and resources you are looking for!
Miltenyi Biotec distribution:
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
For immediate technical support, use our live chat. Connect with us
Phone: +1 866 811 4466
Fax: +1 877 591 1060
Technical support - Research products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
Technical support - Clinical products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
The ability of specific bone marrow cells to slowly proliferate and adhere to plastic was first described in the early 1970s (PMID: 4455512). Named colony-forming-unit fibroblasts (CFU-Fs) because of their spindle-like morphology, these cells showed non-hematopoietic differentiation potential. Eventually, the cells became known as mesenchymal stem cells or mesenchymal stromal cells (MSC) and a set of minimal defining criteria were established in 2006 to accelerate new discoveries, and facilitate data comparability and development of novel cellular therapies (PMID: 16923606).
Minimal criteria for defining multipotent mesenchymal stromal cells:
|Bone marrow||1–10 CFU-F clones per 1x106 mononuclear cells||CD271, Anti-MSCA-1|
|Adipose tissue||n/a||CD34, CD146, CD271|
|Umbilical cord blood||1 CFU-F clone per 1x108 mononuclear cells to 1–3 CFU-F clones per 1x106 mononuclear cells||n/a|
|Amniotic epithelium||n/a||CD271, Frizzled-9|
Miltenyi Biotec has created dedicated applications for the isolation, expansion and analysis of MSCs.
Miltenyi Biotec has developed several products for the straightforward magnetic separation of MSCs. In addition, generic protocols are available for indirect separation of MSCs using Anti-biotin or Anti-flurochrome microbeads in combination with biotin- or flurochrome-conjugated antibodies.For details on MACS® Cell Separation Technology, see the MACS Handbook chapter Magnetic Cell Separation.
|Starting material||Isolation strategy||Comments||Automation*||Product|
|Bone marrow, adipose tissue||Positive selection of target cells||High yield and purity of CD271bright population||Yes||CD271 MicroBead Kit, human|
|Bone marrow, adipose tissue||Positive selection of target cells||High purity||Yes||Anti-MSCA-1 (W8B2) MicroBead Kit, human|
|Bone marrow, adipose tissue||Positive selection of target cells||High yield of whole CD271 population||Yes||CD271 MicroBead Kit (APC), human|
|* Automation performed on the autoMACS® Pro Separator|
BM-MNCs before separation
Enrichment of CD271+ mesenchymal stromal cells (MSCs) from bone marrow mononuclear cells (BM-MNCs). MSCs were isolated using the CD271 MicroBead Kit, human, an MS Column, and a MiniMACS™ Separator. Cells were stained with CD271 antibodies conjugated to APC or PE, as well as CD45-FITC and analyzed by flow cytometry using the MACSQuant® Analyzer.
Separation of MSCA-1 (W8B2)-positive MSCs from human bone marrow mononuclear cells (BM-MNCs). Combining the Anti-MSCA-1 MicroBead Kit, with two MS Columns and a MiniMACS™ Separator, the highly proliferative population of MSCs was isolated from other mononuclear cells. Staining was done with Anti-MSCA-1 (W8B2)-APC and CD45-FITC.
|Standardized identification and quantification of MSCs from fresh bone marrow aspirate||More objective method than colony forming unit-fibroblast (CFU-F) assay||MSC Enumeration Kit, human|
|Standardized identification and quantification of cultivated and expanded MSCs||Phenotyping is fast, easy, reliable, and based on ISCT-defined standards||MSC Phenotyping Kit, human|
|Expansion in serum-containing medium||Increases proliferation with CytoMix – MSC||StemMACS™ MSC Expansion Media, human|
|Robust expansion under xeno- and serum-free conditions||Free of animal components and requires no pre-coating of culture vessels with attachment substrates||StemMACS™ MSC Expansion Media Kit XF, human|
|Expansion in serum-free, GMP-grade medium||GMP-grade, animal component-free medium requiring no pre-coating of culture vessels. Includes MSC-Brew GMP Basal Medium, MSC-Brew GMP Supplement R I, and MSC-Brew GMP Supplement II.||MSC-Brew GMP Medium|
|Supplement||Increases proliferation with StemMACS™ MSC Expansion Media, human||CytoMix – MSC, human|
First protocols to isolate and expand MSCs from human tissues were based on FCS-containing media. To meet mounting safety requirements from regulatory authorities, Miltenyi Biotec provides FCS-containing media (StemMACS MSC Expansion Media), serum- and xeno-free media (StemMACS MSC Expansion Media Kit XF), as well as serum- free, GMP- grade media (MSC-Brew GMP Medium). All media enable reliable and reproducible expansion of MSCs from bone marrow, adipose tissue and umbilical cord.StemMACS™ MSC Expansion Media Kit XF is perfect for the direct isolation and expansion of human MSCs from various sources, including bone marrow and lipoaspirate. Its xeno-free composition enables fast expansion while maintaining differentiation potential and immunomodulation ability. MSCs cultured in StemMACS MSC Expansion Media XF show superior expansion rate compared to other standard MSC culture methods.
|Differentiation of MSC to adipocytes||Supports differentiation of MSC derived from various tissue sources||StemMACS™ AdipoDiff Media, human|
|Differentiation of MSC to osteoblasts||Supports differentiation of MSC derived from various tissue sources||StemMACS™ OsteoDiff Media, human|
|Differentiation of MSC to chondrocytes||Supports differentiation of MSC derived from various tissue sources||StemMACS™ ChondroDiff Media, human|
Differentiation potential is a meaningful tool to qualify and define a MSC population. Grade of differentiation into adipocytes, chondrocytes and osteoblasts is influenced by MSC origin, so for example, MSCs from bone marrow show greater potential to differentiate into osteoblasts than MSCs from umbilical cord. Increased age of donor and passaging of cultured MSCs also decrease differentiation potential.StemMACS™ AdipoDiff, OsteoDiff, and ChondroDiff Media are optimized differentiation media for human MSCs from various tissue sources. The media support the analysis or quality control of the differentiation capacity of expanded MSCs, as well as in vitro studies on the processes of MSC differentiation, including gene expression and protein profiling.
MSCs differentiation into adipocytes, chondrocytes or osteoblasts. (A) Adipocytes were stained with Oil Red O after cultivation of MSCs in StemMACS™ AdipoDiff Medium for 21 days. (B) Chondrocytes were stained for aggrecan (red) and nuclei (blue) after cultivation of MSCs in StemMACS™ ChondroDiff Medium for 21 days. (C) Osteoblasts were stained with NBT substrate after cultivation of MSCs in StemMACS™ OsteoDiff Medium for 10 days.
|Functional characterization of human MSCs||Standardized characterization of the immunomodulatory function of MSCs||MSC Suppression Inspector, human|